Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

USA - NASDAQ:SLNO - US8342033094 - Common Stock

69.335 USD
-0.62 (-0.88%)
Last: 10/30/2025, 3:57:02 PM
Fundamental Rating

2

Taking everything into account, SLNO scores 2 out of 10 in our fundamental rating. SLNO was compared to 534 industry peers in the Biotechnology industry. While SLNO seems to be doing ok healthwise, there are quite some concerns on its profitability. SLNO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SLNO had negative earnings in the past year.
SLNO had a negative operating cash flow in the past year.
SLNO had negative earnings in each of the past 5 years.
In the past 5 years SLNO always reported negative operating cash flow.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

SLNO has a Return On Assets (-54.49%) which is comparable to the rest of the industry.
SLNO's Return On Equity of -75.41% is in line compared to the rest of the industry. SLNO outperforms 54.31% of its industry peers.
Industry RankSector Rank
ROA -54.49%
ROE -75.41%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

SLNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, SLNO has more shares outstanding
Compared to 5 years ago, SLNO has more shares outstanding
SLNO has a worse debt/assets ratio than last year.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 21.36 indicates that SLNO is not in any danger for bankruptcy at the moment.
SLNO has a better Altman-Z score (21.36) than 90.45% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that SLNO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.21, SLNO is not doing good in the industry: 68.16% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 21.36
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

SLNO has a Current Ratio of 15.13. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
SLNO's Current ratio of 15.13 is amongst the best of the industry. SLNO outperforms 90.64% of its industry peers.
SLNO has a Quick Ratio of 15.01. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SLNO (15.01) is better than 90.26% of its industry peers.
Industry RankSector Rank
Current Ratio 15.13
Quick Ratio 15.01
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

SLNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.67%.
EPS 1Y (TTM)-69.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SLNO will show a very strong growth in Earnings Per Share. The EPS will grow by 51.83% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y81.5%
EPS Next 2Y65.27%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 200M 400M 600M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLNO. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 22.25, SLNO is valued on the expensive side.
91.95% of the companies in the same industry are more expensive than SLNO, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.63. SLNO is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 22.25
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SLNO's earnings are expected to grow with 51.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.27%
EPS Next 3Y51.83%

More info and screens

0

5. Dividend

5.1 Amount

SLNO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (10/30/2025, 3:57:02 PM)

69.335

-0.62 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners108.63%
Inst Owner Change-0.28%
Ins Owners1.42%
Ins Owner Change0.24%
Market Cap3.69B
Revenue(TTM)32.66M
Net Income(TTM)-181079000
Analysts85.88
Price Target121.1 (74.66%)
Short Float %16.3%
Short Ratio4.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.18%
Min EPS beat(2)-0.42%
Max EPS beat(2)80.77%
EPS beat(4)1
Avg EPS beat(4)-28.52%
Min EPS beat(4)-186.49%
Max EPS beat(4)80.77%
EPS beat(8)2
Avg EPS beat(8)-30.55%
EPS beat(12)5
Avg EPS beat(12)-17.7%
EPS beat(16)8
Avg EPS beat(16)-9.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.11%
PT rev (3m)4.15%
EPS NQ rev (1m)0.51%
EPS NQ rev (3m)109.71%
EPS NY rev (1m)3.68%
EPS NY rev (3m)75.4%
Revenue NQ rev (1m)2.84%
Revenue NQ rev (3m)44.96%
Revenue NY rev (1m)1.82%
Revenue NY rev (3m)196.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 22.25
P/S 112.84
P/FCF N/A
P/OCF N/A
P/B 15.35
P/tB 15.73
EV/EBITDA N/A
EPS(TTM)-4.14
EYN/A
EPS(NY)3.12
Fwd EY4.49%
FCF(TTM)-1.59
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0.61
BVpS4.52
TBVpS4.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.49%
ROE -75.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.53%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.13
Quick Ratio 15.01
Altman-Z 21.36
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.21%
EPS Next Y81.5%
EPS Next 2Y65.27%
EPS Next 3Y51.83%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-165.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-283.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-282.33%
OCF growth 3YN/A
OCF growth 5YN/A

SOLENO THERAPEUTICS INC / SLNO FAQ

What is the ChartMill fundamental rating of SOLENO THERAPEUTICS INC (SLNO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SLNO.


What is the valuation status for SLNO stock?

ChartMill assigns a valuation rating of 3 / 10 to SOLENO THERAPEUTICS INC (SLNO). This can be considered as Overvalued.


How profitable is SOLENO THERAPEUTICS INC (SLNO) stock?

SOLENO THERAPEUTICS INC (SLNO) has a profitability rating of 1 / 10.


What is the expected EPS growth for SOLENO THERAPEUTICS INC (SLNO) stock?

The Earnings per Share (EPS) of SOLENO THERAPEUTICS INC (SLNO) is expected to grow by 81.5% in the next year.